SCHEMBL9937430

SCHEMBL9937430

O=C(O)C(CS)N1C(=O)CC(Cc2ccc(O)cc2O)C1=O

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MME P08473 1/20 0.43
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
TYR P14679 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
TSHR P16473 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPK1 P28482 1/20 0.32
ALOX5 P09917 1/20 0.31
CA3 P07451 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16529951 0.89 MME (0.56) MMEMEN1KMT2ATYRL3MBTL1
SCHEMBL15328999 0.88 MME (0.46) MMEMEN1KMT2ATYRL3MBTL1
SCHEMBL9968848 0.87 MME (0.37) MMEL3MBTL1
SCHEMBL9968846 0.86 POLB (0.47) MMEMEN1KMT2AL3MBTL1TSHR
SCHEMBL9937977 0.86 MME (0.50) MMETYR
SCHEMBL16529879 0.86 MEN1 (0.45) MMEMEN1KMT2ATYRL3MBTL1
SCHEMBL16530080 0.85 ALDH1A1 (0.50) MMEKMT2AL3MBTL1TSHRALDH1A1
SCHEMBL9937168 0.85 MME (0.44) MMEMEN1KMT2ATYRL3MBTL1
SCHEMBL15341183 0.84 MME (0.49) MMETYRL3MBTL1TSHRALDH1A1
SCHEMBL9968845 0.84 MME (0.42) MMEMEN1KMT2ATYRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651886-B1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES ORÉAL L (FR) 2015-03-04 EP claimed
US-8937187-B2 Method for depigmenting keratin materials using resorcinol derivatives L'OREAL (FR) 2015-01-20 US claimed
US-20130281507-A1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES L'OREAL (FR) 2013-10-24 US claimed
EP-2651886-A1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES L'Oréal (FR) 2013-10-23 EP claimed
WO-2012079938-A1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES L'OREAL (FR) 2012-06-21 WO claimed
EP-2651886-B1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES ORÉAL L (FR) 2015-03-04 EP disclosed
EP-2651886-B1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES ORÉAL L (FR) 2015-03-04 EP disclosed
US-8937187-B2 Method for depigmenting keratin materials using resorcinol derivatives L'OREAL (FR) 2015-01-20 US disclosed
US-8937187-B2 Method for depigmenting keratin materials using resorcinol derivatives L'OREAL (FR) 2015-01-20 US disclosed
US-8937187-B2 Method for depigmenting keratin materials using resorcinol derivatives L'OREAL (FR) 2015-01-20 US disclosed
US-20130281507-A1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES L'OREAL (FR) 2013-10-24 US disclosed
US-20130281507-A1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES L'OREAL (FR) 2013-10-24 US disclosed
US-20130281507-A1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES L'OREAL (FR) 2013-10-24 US disclosed
WO-2012079938-A1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES L'OREAL (FR) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281507-A1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES KRT18, KLHL20, IK MME 2679/4885MEN1 2634/4885KMT2A 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.